Company Overview of Hetero Drugs Limited
Hetero Drugs Limited, a pharmaceutical company, develops, manufactures, and markets active pharmaceutical ingredients (APIs), intermediate chemicals, and generic finished dosages for the biopharmaceutical industry. It offers APIs, including cytotoxics to the pharmaceutical companies that manufacture formulations and other products; generic formulations; CPS; biologics; anti-retroviral drugs; and biosimilars, including monoclonal antibodies. The company also develops formulations, novel drug delivery systems, new chemical entities, and more. In addition, it provides research and manufacturing services for various pharmaceutical companies; and franchises its operations. It offers its products ...
Hetero Corporate Industrial Estates
Founded in 1993
Key Executives for Hetero Drugs Limited
Director of Production and Whole Time Director
Compensation as of Fiscal Year 2017.
Hetero Drugs Limited Key Developments
Oasmia Pharmaceutical AB Enter into A New Exclusive Marketing and Distributions Agreement with Hetero Group
Jun 14 17
Oasmia Pharmaceutical AB has entered into a new exclusive marketing and distributions agreement with Hetero Group with the goal of driving revenue in Russia and other CIS markets. Under the agreement, Hetero will be responsible for the marketing and distribution of Paclical in Russia and several other markets spanning CIS markets, including Ukraine and Kazakhstan. The relationship is a significant one for Oasmia, as Hetero possesses a large distribution and sales operation in the region and will be investing its own resources into the marketing of Paclical and future Oasmia products Doxophos and Docecal, for which they have an option to distribute. The terms in the agreement are similar to the previous agreement for the region. Oasmia and Hetero Group have also signed a letter of intent regarding India and South America, which will be negotiated separately.
Hetero gets Drug Controller-General of India Nod for Hepatitis C Generic
May 5 17
Hetero has received approval for the generic version of Sofosbuvir and Velpatasvir combination drug from the Drug Controller-General of India. The approved drug is a generic of Gilead’s Epclusa brand and is indicated for the treatment of chronic Hepatitis C genotype 1 to 6. It will be distributed and marketed in the domestic market under the brand Velasof by Hetero Healthcare. This product will be launched under a non-exclusive agreement with Gilead Science Inc, which allows it to manufacture and sell generic versions of its chronic Hepatitis C medicines in 101 developing countries.
Hetero Bags DCG(I) Approval for Generic Version of Daclatasvir Tablets
Dec 14 15
Hetero has received the approval from Drug Controller General (India) for the generic version of Daclatasvir tablets (30mg, 60mg). The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India. The product is a generic version of Bristol-Myers Squibb's brand 'Daklinza,' approved by US FDA in July 2015. Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment. Research studies indicates that this drug enables the rapid decline of Hepatitis C virus. Daclatasvir is included the World Health Organization's List of Essential medicines.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries